217 related articles for article (PubMed ID: 29204993)
1. Update on the Use of Anti-VEGF Intravitreal Therapies for Retinal Vein Occlusions.
Jiang Y; Mieler WF
Asia Pac J Ophthalmol (Phila); 2017; 6(6):546-553. PubMed ID: 29204993
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
4. Use of Anti-VEGF Drugs in Retinal Vein Occlusions.
Vilela MA
Curr Drug Targets; 2020; 21(12):1181-1193. PubMed ID: 32342813
[TBL] [Abstract][Full Text] [Related]
5. Retinal Vein Occlusion.
Sawada O; Ohji M
Dev Ophthalmol; 2016; 55():147-53. PubMed ID: 26501219
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials in Branch Retinal Vein Occlusion.
Panakanti TK; Chhablani J
Middle East Afr J Ophthalmol; 2016; 23(1):38-43. PubMed ID: 26957837
[TBL] [Abstract][Full Text] [Related]
8. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
Zhou S; Gao J; Xu X
Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
10. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
11. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
[TBL] [Abstract][Full Text] [Related]
12. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
13. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
Hu Q; Li H; Xu W; Du Y; Ma C; He J
Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
[TBL] [Abstract][Full Text] [Related]
15. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA; Ip MS; Kulkarni AD
Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
[TBL] [Abstract][Full Text] [Related]
16. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of off-label anti-vascular endothelial growth factor and steroid implant medication uses in macular edema due to retinal vein occlusion in Turkey.
Yilmaz M; Citirik M; Rahmanlar H; Alkan A; Gursoz H
J Clin Pharm Ther; 2022 Dec; 47(12):2101-2106. PubMed ID: 36543255
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion.
Hogg HJ; Di Simplicio S; Pearce MS
Eur J Ophthalmol; 2021 Mar; 31(2):548-555. PubMed ID: 32009462
[TBL] [Abstract][Full Text] [Related]
19. Best practices for treatment of retinal vein occlusion.
Hahn P; Fekrat S
Curr Opin Ophthalmol; 2012 May; 23(3):175-81. PubMed ID: 22450223
[TBL] [Abstract][Full Text] [Related]
20. RETINAL VEIN OCCLUSIONS, FROM BASICS TO THE LATEST TREATMENT.
Ho M; Liu DT; Lam DS; Jonas JB
Retina; 2016 Mar; 36(3):432-48. PubMed ID: 26716954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
